Subcutaneous semaglutide is effective for weight loss in individuals with obesity without diabetes, achieving an average reduction of 11.85% from baseline compared to placebo. However, the treatment is associated with a higher risk of gastrointestinal adverse events, treatment discontinuation, and serious adverse event
The prevalence of cardiometabolic multimorbidity (co-existence of ≥1 cardiometabolic diseases) in the U.S. has been increasing significantly from 1999 to 2018, with a prevalence of 14.4% in 2017-2018. This trend was observed in both genders, most age groups, and non-Hispanic White people. The most common patterns were hypertension and diabetes, hypertension, diabetes, and CHD, and hypertension and CHD. This highlights the growing concern of cardiometabolic multimorbidity as a public health issue in the U.S.
Recent guidelines for managing type 2 diabetes mellitus (T2D) emphasize a personalized approach over rigid treatment algorithms, aiming to enhance patient satisfaction, medication adherence, and overall health outcomes. This strategy involves tailoring treatment goals based on individual medical and patient factors, ultimately reducing costs and complications associated with diabetes management.
The accumulation of an excessive amount of body fat can cause type 2 diabetes, and the risk of type 2 diabetes increases linearly with an increase in body mass index. Accordingly, the worldwide increase in the prevalence of obesity has led to a concomitant increase in the prevalence of type 2 diabetes.
Why does obesity cause diabetes? Read More »
This study examined the association between cardiometabolic diseases (MI, stroke, and diabetes) and all-cause mortality in 2 million patients. Results showed that having all three conditions increased the risk of mortality, but this excess risk was not significantly greater than expected from the individual diseases. The presence of other comorbidities also contributed to the excess mortality risks associated with cardiometabolic disease multimorbidity.
Obesity and overweight are independent risk factors of erectile dysfunction (ED). It is controversial whether weight loss can improves erectile function. We thereby performed this meta-analysis to clarify the therapeutic effect of weight loss on erectile function in overweight or obese men.
The research highlights the increased severity of COVID-19 in patients with diabetes mellitus, noting that hyperglycaemia may worsen outcomes by affecting immune responses. It suggests that insulin should be the primary treatment for managing acute glycaemia in these patients, while the effects of glucose-lowering medications like DPP4 inhibitors and SGLT2 inhibitors remain uncertain. Further investigation into the management of diabetes in the context of COVID-19 is needed.
COVID-19 and diabetes mellitus: from pathophysiology to clinical management Read More »
This study estimates the prevalence of central obesity in South Asian adults and examines gender differences in central obesity across cardiometabolic determinants.
This site is only for use by healthcare professionals.
By continuing to view this site you are confirming that you are a healthcare professional.
